Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 09, 2019; 92 (15 Supplement) May 5, 2019

A 12-month, open-label, repeat-dose safety study of Valtoco ™ (NRL-1, diazepam nasal spray) in patients with epilepsy: Interim report (P1.5-028)

Michael Sperling, Robert Hogan, Victor Biton, Daniel Tarquinio, Enrique Carrazana, DIAZ 001.05 Study Group
First published April 16, 2019,
Michael Sperling
1Thomas Jefferson University Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Hogan
2Washington Univ in St Louis/Neuro Dept Saint Louis MO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor Biton
3AEP Little Rock AR United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Tarquinio
4Center for Rare Neurological Diseases Norcross GA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enrique Carrazana
5Neurelis San Diego CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
5Neurelis San Diego CA United States
Citation
A 12-month, open-label, repeat-dose safety study of Valtoco ™ (NRL-1, diazepam nasal spray) in patients with epilepsy: Interim report (P1.5-028)
Michael Sperling, Robert Hogan, Victor Biton, Daniel Tarquinio, Enrique Carrazana, DIAZ 001.05 Study Group
Neurology Apr 2019, 92 (15 Supplement) P1.5-028;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To assess the long term safety of diazepam after repeat intranasal doses of Valtoco™ (NRL-1, diazepam nasal spray), formulated with Intravail® A3, administered to patients with epilepsy who experience frequent breakthrough seizures or Acute Repetitive Seizures (ARS), over 12-months.

Background: Valtoco is designed as an easy-to-use, non-invasive treatment by care-partners outside the medical setting for bouts of seizures.

Design/Methods: In this repeat dose, open-label trial, Valtoco was administered as needed to treat bouts of diagnosed seizures over a 12-month period of time. Doses were defined as 5 mg, 10 mg, 15 mg, or 20 mg based on the subject’s age and body weight, and were modified by the investigators as needed. Patients diaries documented time and duration of seizures and outcome.

Results: Of the 121 patients enrolled to date in this interim analysis, 109 patients (14 < 12 years of age) received at least one dose of Valtoco and were included in the safety population. There was a total of 1585 seizure episodes treated with Valtoco in 109 patients in the safety population (1 to >40 doses).

A single dose was adequate for seizure control in 92% (1457) of seizure episodes.

Overall, 67 out of 109 patients (61.5%) had at least one adverse event (AE). Nineteen patients (17.4%) had AEs that were considered treatment-related by the Investigator. The most frequent treatment-related events were nasal discomfort (7 patients, 6.4%), and epistaxis, headache (4 patients, 8.2%). Of the 67 patients experiencing AEs, 18 patients had 30 AEs that were considered serious, none of which was considered treatment-related by the Investigators.

Conclusions: Overall, this study demonstrates that Valtoco is safe and well tolerated in subjects with epilepsy who have frequent breakthrough seizures. Relatively few of the reported AEs were treatment related, and these were generally mild or moderate in severity. No SAEs were attributable to Valtoco.

Disclosure: Dr. Sperling has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Medtronic. Dr. Sperling has received research support from Eisai, Medtronic, Neurelis, Pfizer, SK Life Science, Takeda, Sunovion, UCB Pharma and Upsher-Smith. Dr. Hogan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with SK Chemical. Dr. Hogan has received research support from UCB Pharmaceuticals, Neurelis Pharnaceuticals, Biogen Inc. Dr. Biton has nothing to disclose. Dr. Tarquinio has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Marinus and Avexis. Dr. Carrazana has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Neurelis, Marinus, Zogenix, Praxis, Adamas, Ovid, Epalex, Aeromics, Alexza. Dr. Carrazana has received compensation for serving on the Board of Directors of Marinus Pharmaceuticals, Epalex. Dr. Novack has nothing to disclose.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (12)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise